Skip to main content

Table 5 Univariate analysis for first skeletal-related event

From: Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity

Variable

RR

(95% CI)

pvalue

Age ≥ 50 years

0.94

(0.63, 1.40)

0.760

ECOG performance status

   

   2 – 3 versus 0 – 1

1.81

(1.21, 2.72)

0.004

Hydroxyproline/Creatinine ratio (centered)

1.00

(0.97, 1.04)

0.921

Bone-specific alkaline phosphatase, U/L

1.01

(1.00, 1.01)

0.204

Estrogen-receptor status versus negative

   

   Positive

0.56

(0.34, 0.92)

0.023

   Unknown

0.89

(0.58, 1.36)

0.580

Progesterone-receptor status versus negative

   

   Positive

0.62

(0.38, 1.01)

0.053

   Unknown

0.78

(0.52, 1.16)

0.214

Sites of metastasis (yes versus no)

   

   Bone as only metastatic site

0.84

(0.57, 1.24)

0.392

   Lung

1.32

(0.77, 2.29)

0.317

   Liver

1.26

(0.75, 2.13)

0.379

Time from diagnosis of bone metastases to study entry, years

1.00

(0.95, 1.04)

0.912

Time from cancer diagnosis to study entry, years

1.00

(0.96, 1.04)

0.947

Lesion characteristics and numbers

   

   ≥ 3 osteolytic versus < 3 osteolytic

1.92

(1.29, 2.84)

0.001

   1 – 2 osteoblastic versus no osteoblastic

1.28

(0.82, 2.02)

0.282

   ≥ 3 osteoblastic versus no osteoblastic

0.39

(0.32, 0.50)

< 0.001

   1 – 2 mixed versus no mixed

1.16

(0.64, 2.09)

0.624

   ≥ 3 mixed versus no mixed

1.26

(0.77, 2.06)

0.352

Prior fracture (yes versus no)

1.78

(1.12, 2.81)

0.014

Pain scores (centered)

1.29

(1.19, 1.40)

< 0.001

Prior chemotherapy (yes versus no)

0.89

(0.32, 2.48)

0.816

≥ 2 prior hormonal therapies (yes versus no)

1.11

(0.75, 1.63)

0.605

Prior radiotherapy (yes versus no)

2.02

(1.35, 3.02)

< 0.001

  1. Values in bold represent statistically significant correlations.
  2. RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us